Compare · QTI vs SLNO
QTI vs SLNO
Side-by-side comparison of QT Imaging Holdings Inc. (QTI) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QTI and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 60.4x QTI ($45.8M).
- Over the past year, QTI is down 36.1% and SLNO is down 31.8% - SLNO leads by 4.3 points.
- SLNO has been more active in the news (39 items in the past 4 weeks vs 4 for QTI).
- SLNO has more recent analyst coverage (12 ratings vs 0 for QTI).
- Company
- QT Imaging Holdings Inc.
- Soleno Therapeutics Inc.
- Price
- $3.82+1.33%
- $53.02+0.08%
- Market cap
- $45.8M
- $2.76B
- 1M return
- -46.35%
- +0.76%
- 1Y return
- -36.12%
- -31.78%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 4
- 39
- Recent ratings
- 0
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest QTI
- QT Imaging Receives Saudi Arabia FDA Regulatory Clearance
- QT Imaging Set to Join the Russell Microcap® Index
- QT Imaging Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- QT Imaging Holdings Announces Closing of $10 Million Underwritten Public Offering
- SEC Form 424B5 filed by QT Imaging Holdings Inc.
- QT Imaging Holdings Announces Pricing of $10 Million Underwritten Public Offering
- SEC Form 10-Q filed by QT Imaging Holdings Inc.
- QT Imaging Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- QT Imaging Reports First Quarter 2026 Revenue of $6.5 Million
- Leading Breast Surgical Oncologist Dr. Barry Roseman to Serve as Senior Medical Advisor to QT Imaging
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)